Influence of three dimensional conformal radiation therapy combined with chemotherapy on Treg in peripheral blood of esophagus carcinoma patients

doi:10.3969/j.issn.1673-8640.2017.05.010

Abstract

Abstract:

Objective To investigate the influence of three dimensional conformal radiation therapy （3D-CRT） combined with chemotherapy on CD4⁺Foxp⁺ regulatory T cell （Treg） proportion and transforming growth factor-beta 1 （TGF-β1） level in peripheral blood of esophagus carcinoma patients,and to investigate the internal influence mechanism of 3D-CRT combined with chemotherapy for the treatment of esophagus carcinoma. Methodse Flow cytometry was used to determine Treg proportion in 87 esophagus carcinoma patients and 30 healthy subjects. Serum TGF-β1 level was determined by enzyme-linked immunosorbent assay （ELISA）. The difference of Treg proportion and TGF-β1 level was analyzed among patients undergoing 3D-CRT combined with chemotherapy,patients with single 3D-CRT and healthy subjects. Results Compared to single 3D-CRT group,the Treg proportion and TGF-β1 level in peripheral blood decreased in 3D-CRT combined with chemotherapy group after patients undergoing radiochemotherapy （P<0.05）. Conclusions The 3D-CRT combined with chemotherapy could reduce Treg proportion and TGF-β1 level in peripheral blood of esophagus carcinoma patients,and plays a role for the treatment of esophagus carcinoma.

Key words: Regulatory T cell, Transforming growth factor-beta 1, Three dimensional conformal radiation therapy, Chemotherapy, Esophagus carcinoma

CLC Number:

R446.63

XU Xinxin, WANG Yungang, CAI Hua, SHEN Pei, CHU Fuying. Influence of three dimensional conformal radiation therapy combined with chemotherapy on Treg in peripheral blood of esophagus carcinoma patients[J]. Laboratory Medicine, 2017, 32(5): 390-393.

Figures/Tables 2

References 13

[1]	LING T C,SLATER J M,NOOKALA P,et al.Analysis of intensity-modulated radiation therapy (IMRT),proton and 3D conformal radiotherapy (3D-CRT) for reducing perioperative cardiopulmonary complications in esophageal cancer patients[J]. Cancers (Basel), 2014, 6(4): 2356-2368.
[2]	LOOMANS H A,ANDL C D.Intertwining of activin A and TGFβ signaling:dual roles in cancer progression and cancer cell invasion[J]. Cancers (Basel),2014, 7(1):70-91.
[3]	WANG G,SUN Y,JI C,et al.Correlation between the CD4+ CD25high regulatory T cells and the outcome of chemotherapy in advanced esophageal carcinoma[J]. Hepatogastroenterology,2013,60(124):704-708.
[4]	REGINATO E,LINDENMANN J,LANGNER C,et al.Photodynamic therapy downregulates the function of regulatory T cells in patients with esophageal squamous cell carcinoma[J]. Photochem Photobiol Sci,2014,13(9):1281-1289.
[5]	卢剑,袁向亮,沈立松. 消化道肿瘤局部和其他部位调节性T细胞表面标志表达的差异[J]. 检验医学,2008,23(2):163-167.
[6]	谷伟伟. 调节性T细胞与肿瘤相互作用机制的研究进展[J]. 医学综述,2012,18(5):680-684.
[7]	张建,黄艳春,程真珍. 哈萨克族食管癌外周血CD4+ CD25+ Foxp3+调节性T细胞与TGF-β-1、IL-10的相关性研究[J]. 新疆医科大学学报,2011,34(1):70-73.
[8]	FRIMPONG-BOATENG K,VAN ROOIJEN N,GEIBEN-LYNN R.Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice,blunting the CD8+ T cell immune response by the cytokine TGFbeta[J]. PLoS One,2010,5(8):e12281.
[9]	HADASCHIK E N,ENK A H.TGF-β1-induced regulatory T cells[J]. Hum Immunol,2015,76(8):561-564.
[10]	SCHON H T,WEISKIRCHEN R.Immuno- modulatory effects of transforming growth factor-β in the liver[J]. Hepatobiliary Surg Nutr,2014,3(6):386-406.
[11]	WONG R K,MALTHANER R A,ZURAW L,et al.Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus:a practice guideline[J]. Int J Radiat Oncol Biol Phys,2003,55(4):930-942.
[12]	黄升武,黄广优,邓柑雀. 三维适形放疗同步化疗治疗中晚期食管癌的疗效观察[J]. 广西医学,2011,33(2):197-199.
[13]	赵维勇,张丽珍,王继荣. 三维适形放疗联合不同化疗方案治疗中晚期食管癌的临床研究[J]. 现代肿瘤医学,2012,20(5):956-958.

组别	例数	Treg占CD4⁺ T细胞的比例（%）		TGF-β1水平（ng/L）
组别	例数	放化疗前	放化疗后	放化疗前	放化疗后
正常对照组	30	1.35±1.32	1.35±1.32	49.70±6.20	49.70±6.20
3D-CRT组	39	6.30±1.73^**	4.20±1.78^**	134.70±15.47^**	76.40±5.48^*
3D-CRT联合化疗组	48	5.80±1.64^**	2.20±1.81^{* #}	138.30±18.95^**	54.30±4.81^#

组别	例数	Treg占CD4⁺ T细胞的比例（%）		TGF-β1水平（ng/L）
组别	例数	放化疗前	放化疗后	放化疗前	放化疗后
正常对照组	30	1.35±1.32	1.35±1.32	49.70±6.20	49.70±6.20
3D-CRT组	39	6.30±1.73^**	4.20±1.78^**	134.70±15.47^**	76.40±5.48^*
3D-CRT联合化疗组	48	5.80±1.64^**	2.20±1.81^{* #}	138.30±18.95^**	54.30±4.81^#

[1]	YUAN Shuang, FENG Lei, GUO Xiaofen, FU Xiaoling, XU Jing, LIU Hongyang. Relation of miR-433 in endometrial cancer tissues and its relationship with chemotherapy sensitivity [J]. Laboratory Medicine, 2023, 38(4): 337-341.
[2]	CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256.
[3]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[4]	WEN Jing, SHI Rui, XIE Jia, LIU Feng, LI Guang, REN Jingjing, LEI Xiaoru, GUO Xiaobo, SONG Yanping. Clinical application of metagenomic next-generation sequencing for determining pathogens in febrile neutropenic patients [J]. Laboratory Medicine, 2022, 37(9): 855-859.
[5]	LIANG Chunfang, ZHU Kangning, ZHANG Qi. Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy [J]. Laboratory Medicine, 2022, 37(5): 417-422.
[6]	GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine：from accurate diagnosis to precision chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 309-312.
[7]	WANG Jianying, WANG Shanshan, ZHU Jun, HUANG Xiaochun, WAN Yuxiang, LIU Yun. Distribution and drug resistance of respiratory infection pathogens in patients with lung cancer after chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 356-359.
[8]	MAN Xianfeng, HE Xiaoting, ZHANG Ying, YU Weiwei, WANG Qi, YIN Hanwei, WANG Runjie. Application of thioredoxin reductase in monitoring the curative effect of lung cancer [J]. Laboratory Medicine, 2022, 37(1): 56-59.
[9]	LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718.
[10]	YANG Yong. Roles of SCC-Ag,CA19-9 and VEGF for chemotherapy efficacy in advanced esophageal squamous cell carcinoma [J]. Laboratory Medicine, 2021, 36(1): 20-24.
[11]	ZHANG Xiaoying. Relationship between the changes of TK1 and ID-1 levels and curative effect in cervical cancer patients before and after neoadjuvant chemotherapy [J]. Laboratory Medicine, 2020, 35(2): 108-111.
[12]	ZOU Guanghui, SUN Fenyong, DAI Jiaqi, YAN Jie, ZHANG Yun, YIN Zhiqiang. Role of follicular regulatory T cells in the pathogenesis of Hashimoto thyroiditis [J]. Laboratory Medicine, 2019, 34(8): 682-686.
[13]	DONG Huan, LIU Xiaoyi, CAI Yanqing, CHEN Xinliang, WANG Xianjing. Difference of the expressions of ER,VEGF and TGF-β1 between multiple EP and single EP patients and their prognosis analysis [J]. Laboratory Medicine, 2019, 34(5): 415-420.
[14]	ZHAO Lian, HE Jinlong, WU Cuiyun, ZHOU Haiyan, ZHOU Weilun, WU Cuiping. Role of peripheral blood CD4⁺CD25^highTreg percentage in the prognosis of ALL [J]. Laboratory Medicine, 2019, 34(4): 327-330.
[15]	KE Xing, ZHANG Liang, SHEN Lisong. Preliminary study on the mechanism of CD4⁺CD25^highCD127^low regulatory T cells promoting the metastasis of epithelial ovarian cancer [J]. Laboratory Medicine, 2019, 34(2): 110-115.